Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP)

factsheet Factsheet
  • Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $36 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-18 Mln

Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP) Share Price

$18.80

As on 04-Mar-2024 09:47 EST

up-down-arrow $0.070.37%

  • Prev Close info

    $18.73

  • Day's Openinfo

    $19.40

  • Today's Highinfo

    $19.40

  • Today's Lowinfo

    $18.70

  • Today's Volumeinfo

    1,584

  • 52 Week rangeinfo

    $5.25 - 22.58

Please wait...

Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP)
15.20 -6.23 105.46 23.04 36.14 28.92 7.51
S&P BSE Sensex*
1.99 2.21 6.99 23.19 13.16 15.36 13.26
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 04-Mar-2024  |  *As on 05-Mar-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP)
48.23 77.30 -5.63 56.24
S&P Small-Cap 600
13.89 -17.42 25.27 9.57
S&P BSE Sensex
18.74 4.44 21.99 15.75

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP)

        President, CEO & Executive Director

        Mr. Spiro George Rombotis

        Executive VP of Finance, CFO, COO, Secretary & Executive Director

        Mr. Paul McBarron

        Headquarters

        Berkeley Heights, NJ

        FAQs for Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP)

        The total asset value of Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP) stood at $ 20 Mln as on 30-Sep-23

        The share price of Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP) is $18.80 (NASDAQ) as of 04-Mar-2024 09:47 EST. Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP) has given a return of 36.14% in the last 3 years.

        Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP) has a market capitalisation of $ 36 Mln as on 29-Feb-2024. As per Value Research classification, it is a Small Cap company.

        Since, TTM earnings of Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP) and enter the required number of quantities and click on buy to purchase the shares of Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP).

        Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey. Address: 200 Connell Drive, Berkeley Heights, NJ, United States, 07922

        The CEO & director of Mr. Spiro George Rombotis. is Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP), and CFO & Sr. VP is Mr. Paul McBarron.

        The promoters of Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP) have pledged 0% of the total equity as on Sep-23.

        Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP) Ratios
        Return on equity(%)
        -260.81
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        3.24

        No, TTM profit after tax of Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (CYCCP) was $-18 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $35.84 Mln
        • Revenue (TTM)revenue-information $0.39 Mln
        • Earnings (TTM) earning-information $-18.47 Mln
        • Cash date-information $5.94 Mln
        • Total Debt info $0.05 Mln
        • Insider's Holding 0.48%
        • Liquidity liquidity Low
        • 52 Week range week-range $5.25 - 22.58
        • Shares outstanding share-outstanding 12,497,400
        • 10 Years Aggregate:

          CFO: $-131.54 Mln

          EBITDA: $-143.76 Mln

          Net Profit: $-141.34 Mln

        About The Company

        • IPO Date 30-Nov-2005
        • President, CEO & Executive Director Mr. Spiro George Rombotis
        • Executive VP of Finance, CFO, COO, Secretary & Executive Director Mr. Paul McBarron
        • Listing key-listing NASDAQ: CYCCP
        • Country United States
        • Headquarters headquarters Berkeley Heights, NJ
        • Website website https://www.cyclacel.com
        • Business

          Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK)...  that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey. Address: 200 Connell Drive, Berkeley Heights, NJ, United States, 07922  Read more

        share-fund-plan-icon